Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.37 |
| ▸ | MC5R | P33032 | 2/20 | 0.37 |
| ▸ | MC3R | P41968 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 5/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 6/20 | 0.35 |
| ▸ | CCND1 | P24385 | 6/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | TACR2 | P21452 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970625 | 0.94 | MC4R (0.35) | MC4RMC5RMC3RHTR1ACDK4 | |
| SCHEMBL1968324 | 0.91 | HTR1A (0.44) | HTR1ACDK4CCND1SLC6A4 | |
| SCHEMBL1971772 | 0.89 | MC4R (0.47) | MC4RMC5RMC3RHTR1ACDK4 | |
| SCHEMBL1970552 | 0.87 | MC4R (0.36) | MC4RMC5RMC3RHTR1ACDK4 | |
| SCHEMBL1967560 | 0.86 | CDK4 (0.49) | MC4RMC5RMC3RCDK4CCND1 | |
| SCHEMBL1970634 | 0.85 | CDK4 (0.47) | MC4RMC5RMC3RCDK4CCND1 | |
| SCHEMBL1971745 | 0.82 | CDK4 (0.50) | MC4RMC5RMC3RCDK4CCND1 | |
| SCHEMBL1970004 | 0.82 | CDK4 (0.48) | MC4RMC5RMC3RCDK4CCND1 | |
| SCHEMBL1967743 | 0.82 | CDK4 (0.41) | MC4RMC5RMC3RCDK4CCND1 | |
| SCHEMBL1979690 | 0.81 | NTRK1 (0.36) | MC4RMC5RMC3RHTR1ACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | MC4R 58/4885MC5R 116/4885MC3R 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.